商用定量hCG免疫分析法在滋养细胞与非滋养细胞疾病中作为肿瘤标志物的效用
研究评估5种定量hCG免疫分析法在150例妊娠滋养细胞疾病、生殖细胞肿瘤或其他恶性肿瘤患者残留标本中作为肿瘤标志物的效用。结果显示hCG升高频率在GTD最高(100%),GCT为55%–57%,其他恶性肿瘤为8%–23%;Roche cobas Total检出升高hCG的标本数最多(63/150)。结论认为5种方法均适用于GTD和部分GCT的肿瘤标志物用途,但系列监测仍需单一方法,方法间需进一步协调。
要点
- GTD中hCG升高频率最高(100%),GCT为55%–57%,其他恶性肿瘤为8%–23%。
- Roche cobas Total检出升高hCG的标本数最多(63/150)。
- 滋养细胞疾病中hCG升高检出率各法几乎等效(范围41–42/60)。
核心结论
- 5种hCG免疫分析法均适用于妊娠滋养细胞疾病和部分生殖细胞肿瘤的肿瘤标志物用途。
- 系列生化肿瘤监测必须使用单一方法,hCG方法间需进一步协调。
- 其他恶性肿瘤中hCG作为肿瘤标志物的效用需额外研究评估。
研究设计与样本
- 回顾性分析150例妊娠滋养细胞疾病、生殖细胞肿瘤或其他恶性肿瘤患者的残留标本。
- 采用5种分析平台进行分标本hCG检测:Abbott Architect Total、Roche cobas STAT、Roche cobas Total、Siemens Dimension Vista Total和Beckman Access Total。
主要发现
- hCG升高频率在GTD为100%,GCT为55%–57%,其他恶性肿瘤为8%–23%。
- Roche cobas Total检出升高hCG的标本数最多(63/150)。
- 滋养细胞疾病中hCG升高检出率各法几乎等效(范围41–42/60)。
临床怎么用
- 在GTD和部分GCT中可将定量hCG作为肿瘤标志物,但系列监测需固定使用单一方法。
局限性
- 其他恶性肿瘤中hCG作为肿瘤标志物的效用需额外研究评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of quantitative human chorionic gonadotropin (hCG) as a tumor marker is widely accepted despite lack of FDA-approval for oncology. Differences in iso- and glycoform recognition among hCG immunoassays is well established, exhibiting wide inter-method variability. Here, we assess the utility of 5 quantitative hCG immunoassays for use as tumor markers in trophoblastic and non-trophoblastic disease. METHODS: Remnant specimens were obtained from 150 patients with gestational trophoblastic disease (GTD), germ cell tumors (GCT), or other malignancies. Specimens were identified by review of results from physician-ordered hCG and tumor marker testing. Five analyzer platforms were used for split specimen analysis of hCG: Abbott Architect Total, Roche cobas STAT, Roche cobas Total, Siemens Dimension Vista Total, and Beckman Access Total. RESULTS: Frequency of elevated hCG concentrations (above reference cutoffs) was highest in GTD (100%), followed by GCT (55% to 57%), and other malignancies (8% to 23%). Overall, the Roche cobas Total detected elevated hCG in the greatest number of specimens (63/150). Detection of elevated hCG in trophoblastic disease was nearly equivalent among all immunoassays (range, 41 to 42/60). CONCLUSIONS: While no immunoassay is likely to be perfect in all clinical situations, results for the 5 hCG immunoassays evaluated suggest that all are adequate for use of hCG as a tumor marker in gestational trophoblastic disease and select germ cell tumors. Further harmonization of hCG methods is needed as serial testing for biochemical tumor monitoring must still be performed using a single method. Additional studies are needed to assess the utility of quantitative hCG as a tumor marker in other malignant disease.
引用
- Franks CE, Li J, Martinez M, et al. Utility of Commercially Available Quantitative hCG Immunoassays as Tumor Markers in Trophoblastic and Non-Trophoblastic Disease. Clin Chem. 2023. PMID: 37205831. doi:10.1093/clinchem/hvad045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。